PL1906939T3 - Zastosowanie częściowo zobojętnianego, anionowego kopolimeru (met)akrylanowego jako powłoki do wytwarzania postaci leku z uwalnianiem substancji czynnej przy obniżonych wartościach pH - Google Patents

Zastosowanie częściowo zobojętnianego, anionowego kopolimeru (met)akrylanowego jako powłoki do wytwarzania postaci leku z uwalnianiem substancji czynnej przy obniżonych wartościach pH

Info

Publication number
PL1906939T3
PL1906939T3 PL06724062.2T PL06724062T PL1906939T3 PL 1906939 T3 PL1906939 T3 PL 1906939T3 PL 06724062 T PL06724062 T PL 06724062T PL 1906939 T3 PL1906939 T3 PL 1906939T3
Authority
PL
Poland
Prior art keywords
meth
anionic
coating
values
production
Prior art date
Application number
PL06724062.2T
Other languages
English (en)
Inventor
Hans-Ulrich Petereit
Manfred Assmus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of PL1906939T3 publication Critical patent/PL1906939T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL06724062.2T 2005-07-12 2006-04-05 Zastosowanie częściowo zobojętnianego, anionowego kopolimeru (met)akrylanowego jako powłoki do wytwarzania postaci leku z uwalnianiem substancji czynnej przy obniżonych wartościach pH PL1906939T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005032806A DE102005032806A1 (de) 2005-07-12 2005-07-12 Verwendung eines teilneutralisierten, anionischen (Meth)acrylat-Copolymers als Überzug für die Herstellung einer Arzneiform mit einer Wirkstofffreisetzung bei erniedrigten pH-Werten

Publications (1)

Publication Number Publication Date
PL1906939T3 true PL1906939T3 (pl) 2016-12-30

Family

ID=37507688

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06724062.2T PL1906939T3 (pl) 2005-07-12 2006-04-05 Zastosowanie częściowo zobojętnianego, anionowego kopolimeru (met)akrylanowego jako powłoki do wytwarzania postaci leku z uwalnianiem substancji czynnej przy obniżonych wartościach pH

Country Status (15)

Country Link
US (1) US7932258B2 (pl)
EP (1) EP1906939B1 (pl)
JP (1) JP5193036B2 (pl)
KR (1) KR101325901B1 (pl)
CN (1) CN101193627A (pl)
BR (1) BRPI0612878A2 (pl)
CA (1) CA2609439C (pl)
DE (1) DE102005032806A1 (pl)
ES (1) ES2588173T3 (pl)
HU (1) HUE028344T2 (pl)
IL (1) IL186553A0 (pl)
MX (1) MX290450B (pl)
PL (1) PL1906939T3 (pl)
SI (1) SI1906939T1 (pl)
WO (1) WO2007006353A2 (pl)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
CA2570916C (en) 2004-06-16 2013-06-11 Tap Pharmaceutical Products, Inc. Pulsed release dosage form of a ppi
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
JP5228359B2 (ja) * 2007-04-12 2013-07-03 ニプロ株式会社 主薬粒子及びその製造方法ならびに口腔内崩壊錠
LT2152250T (lt) * 2007-05-07 2019-12-27 Evonik Operations Gmbh Kietos dozavimo formos, apimančios enterinę dangą su pagreitintu vaisto atpalaidavimu
KR20150084013A (ko) * 2007-10-12 2015-07-21 다케다 파마슈티칼스 유에스에이, 인코포레이티드 음식 섭취와 관계없이 위장 장애를 치료하는 방법
AR070863A1 (es) 2008-03-11 2010-05-12 Takeda Pharmaceutical Preparacion solida de desintegracion oral y metodo para suprimir la ruptura de los granulos finos durante la produccion de un comprimido
EP2236162B1 (de) * 2009-04-02 2013-03-20 InnoTERE GmbH Bioaktiver Knochenzement und Verfahren zu seiner Herstellung
US20100303920A1 (en) * 2009-05-27 2010-12-02 Johan Hjartstam Aqueous Film Coating Composition / 841
PE20120572A1 (es) 2009-07-22 2012-06-06 Gruenenthal Chemie Forma de dosificacion de oxidacion estabilizada resistente a la manipulacion
PE20131102A1 (es) 2010-09-02 2013-10-12 Gruenenthal Chemie Forma de dosificacion resistente a manipulacion que comprende una sal inorganica
LT2736495T (lt) 2011-07-29 2017-11-10 Grünenthal GmbH Sugadinimui atspari tabletė, pasižyminti greitu vaisto atpalaidavimu
DK2736497T3 (da) 2011-07-29 2017-11-13 Gruenenthal Gmbh Stød-resistent tablet, der tilvejebringer en øjeblikkelig frigivelse af et lægemiddel.
CA2885680C (en) 2011-09-07 2022-10-04 Roland Saur-Brosch Formulation for the controlled release of one or several substances in the digestive tract of a mammal.
US10653631B2 (en) 2011-09-07 2020-05-19 Roland SAUR-BROSCH Optimal colon targeting technology
WO2013045352A1 (de) 2011-09-30 2013-04-04 Basf Se Verfahren zur herstellung von festen pigmenthaltigen filmüberzugsmitteln in form von granulaten auf basis von magensaftresistenten filmbildnern für pharmazeutische dosierungsformen
RS57913B1 (sr) * 2012-04-18 2019-01-31 Gruenenthal Gmbh Farmaceutske dozne forme otporne na neovlašćenu upotrebu i naglo oslobađanje celokupne doze
DK2659881T3 (en) 2012-04-30 2018-02-05 Tillotts Pharma Ag Delayed release drug formulation
CN102846386B (zh) * 2012-09-19 2015-02-25 四川大学 智能可控释放抗菌成分的牙种植体及制备方法
US10154966B2 (en) 2013-05-29 2018-12-18 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
MX368846B (es) 2013-07-12 2019-10-18 Gruenenthal Gmbh Forma de dosificación resistente a la alteración que contiene polímero de acetato de etilen-vinilo.
JP6273356B2 (ja) 2013-10-29 2018-01-31 ティロッツ・ファルマ・アクチエンゲゼルシャフトＴｉｌｌｏｔｔｓ Ｐｈａｒｍａ Ａｇ 遅延放出性薬物製剤
EP3073994A1 (en) 2013-11-26 2016-10-05 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of cryo-milling
WO2016066249A1 (en) * 2014-10-28 2016-05-06 Merck Patent Gmbh Preparation of nanoparticles-releasing enteric microparticles
US10842750B2 (en) 2015-09-10 2020-11-24 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CN106317426A (zh) * 2016-08-19 2017-01-11 湖州展望天明药业有限公司 一种可再分散的聚丙烯酸树脂粉末及其制备方法
ES2994844T3 (en) 2018-12-07 2025-02-03 Tillotts Pharma Ag Colonic drug delivery formulation
EP3662898A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG Solid composition comprising mesalazine
EP3662900A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG Colonic drug delivery formulation
ES3002632T3 (en) 2018-12-07 2025-03-07 Tillotts Pharma Ag Delayed release drug formulation comprising an outerlayer with an enzymatically degradable polymer, its composition and its method of manufacturing
EP3662895A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG A process for manufacturing reducing sugar-free 5-asa tablet cores
EP4072533B1 (en) 2019-12-11 2025-01-22 Evonik Operations GmbH Dosage form comprising an alkaline agent and an enteric coating layer
JP7625601B2 (ja) 2019-12-11 2025-02-03 エボニック オペレーションズ ゲーエムベーハー 病気の治療又は予防において使用するための剤形
CN114786652A (zh) 2019-12-11 2022-07-22 赢创运营有限公司 用于治疗或预防疾病的剂型
AU2020413225A1 (en) 2019-12-27 2022-06-23 Evelo Biosciences, Inc. Solid dosage forms containing bacteria and microbial extracellular vesicles
WO2021146523A1 (en) 2020-01-17 2021-07-22 Evelo Biosciences, Inc. Solid dosage forms with improved disintegration profiles
US20230190831A1 (en) 2020-04-17 2023-06-22 Evelo Biosciences, Inc. Solid dosage forms with improved disintegration profiles
MX2023003089A (es) 2020-09-18 2023-05-09 Evelo Biosciences Inc Formas farmaceuticas solidas de bacterias.
WO2022061123A1 (en) 2020-09-21 2022-03-24 Evelo Biosciences, Inc. Solid dosage forms with improved disintegration profiles
AR123960A1 (es) 2020-10-29 2023-01-25 Evelo Biosciences Inc Composiciones que comprenden componentes de espirulina
WO2022125005A1 (en) * 2020-12-08 2022-06-16 Santa Farma Ilac Sanayii A. S. Stable sustained release compositions of acemetacine
US20240058271A1 (en) 2020-12-14 2024-02-22 Kevin Huynh Extracellular vesicle preparations
EP4267154A1 (en) 2020-12-22 2023-11-01 Evelo Biosciences, Inc. Compositions comprising animal hemoglobin
WO2022164806A1 (en) 2021-01-26 2022-08-04 Evelo Biosciences, Inc. Prevotella extracellular vesicle preparations
US20240148797A1 (en) 2021-02-26 2024-05-09 Evelo Biosciences, Inc. Compositions and methods for reducing cytokine expression
WO2022187578A1 (en) 2021-03-05 2022-09-09 Evelo Biosciences, Inc. Solid dosage forms
JP2024516110A (ja) 2021-04-08 2024-04-12 エヴェロ バイオサイエンシズ，インコーポレーテッド 細菌を含有する医薬組成物
WO2022221183A1 (en) 2021-04-12 2022-10-20 Evelo Biosciences, Inc. Fournierella extracellular vesicle preparations
WO2022251166A2 (en) 2021-05-25 2022-12-01 Evelo Biosciences, Inc. Bacterial compositions comprising soy hemoglobin
WO2023049268A1 (en) 2021-09-24 2023-03-30 Evelo Biosciences, Inc. Solid dosage forms containing bacteria and microbial extracellular vesicles
WO2023114293A1 (en) 2021-12-14 2023-06-22 Evelo Biosciences, Inc. Extracellular vesicle assays
WO2023114295A1 (en) 2021-12-14 2023-06-22 Evelo Biosciences, Inc. Veillonella parvula bacteria extracellular vesicle preparations
WO2023114300A1 (en) 2021-12-14 2023-06-22 Evelo Biosciences, Inc. Fournierella massiliensis bacteria extracellular vesicle preparations
WO2023146843A1 (en) 2022-01-25 2023-08-03 Evelo Biosciences, Inc. Extracellular vesicle compositions and methods of use
WO2023183396A1 (en) 2022-03-22 2023-09-28 Evelo Biosciences, Inc. Compositions and methods of treating inflammation using prevotella histicola
WO2023200837A1 (en) 2022-04-13 2023-10-19 Evelo Biosciences, Inc. Compositions and methods of treating inflammation using prevotella histicola
WO2023239728A1 (en) 2022-06-07 2023-12-14 Evelo Biosciences, Inc. Compositions and methods of treating inflammation using prevotella histicola extracellular vesicles
WO2024102226A1 (en) 2022-10-14 2024-05-16 Evelo Biosciences, Inc. Methods for assaying drug substances and drug products by using cell lines with nf-kb- inducible reporter genes
WO2025082974A1 (en) 2023-10-16 2025-04-24 Bioprojet Pharma New formulations of pitolisant and methods of use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT93637A (pt) 1989-04-20 1990-11-20 Procter & Gamble Metodo para o tratamento de desordens funcionais intestinais/colonicas, especialmente o sindrome de irritacao intestinal
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
DE19626045C2 (de) * 1996-06-28 1998-12-03 Klinge Co Chem Pharm Fab Stabile Arzneiform zur oralen Verabreichung, welche Omeprazol als aktiven Wirkstoff enthält, sowie Verfahren zur Herstellung derselben
US6174548B1 (en) * 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
AU2161000A (en) * 1998-12-07 2000-06-26 Bristol-Myers Squibb Company Enteric coated pravastatin bead formulation
MXPA03011031A (es) 2001-05-30 2004-07-08 Euro Celtique Sa Composicion farmaceutica.
DE10208335A1 (de) * 2002-02-27 2003-09-04 Roehm Gmbh Arzneiform und Verfahren zu ihrer Herstellung
DE10260919A1 (de) * 2002-12-20 2004-07-01 Röhm GmbH & Co. KG Verfahren zur Herstellung von überzogenen Arzneiformen und Nahrungsergänzungsmitteln mit Konzentrationsgradienten im Überzug
DE10332160A1 (de) * 2003-07-15 2005-02-03 Röhm GmbH & Co. KG Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Peptid- oder Protein-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
DE102005007059A1 (de) 2005-02-15 2006-08-24 Röhm GmbH & Co. KG Teilneutralisiertes anionisches (Meth)acrylat-Copolymer
ES2385498T3 (es) * 2006-08-18 2012-07-25 Evonik Röhm Gmbh Composición farmacéutica con liberación controlada de la sustancia activa, para sustancias activas con una buena solubilidad en agua

Also Published As

Publication number Publication date
KR101325901B1 (ko) 2013-11-07
BRPI0612878A2 (pt) 2010-11-30
JP2009501163A (ja) 2009-01-15
US7932258B2 (en) 2011-04-26
ES2588173T3 (es) 2016-10-31
SI1906939T1 (sl) 2016-10-28
MX2007015954A (es) 2008-10-27
EP1906939B1 (de) 2016-06-01
WO2007006353A2 (de) 2007-01-18
DE102005032806A1 (de) 2007-01-18
MX290450B (es) 2011-09-23
JP5193036B2 (ja) 2013-05-08
CA2609439C (en) 2013-10-29
US20080200482A1 (en) 2008-08-21
WO2007006353A3 (de) 2007-04-12
KR20080024200A (ko) 2008-03-17
IL186553A0 (en) 2008-01-20
HUE028344T2 (en) 2016-12-28
CN101193627A (zh) 2008-06-04
CA2609439A1 (en) 2007-01-18
EP1906939A2 (de) 2008-04-09

Similar Documents

Publication Publication Date Title
PL1906939T3 (pl) Zastosowanie częściowo zobojętnianego, anionowego kopolimeru (met)akrylanowego jako powłoki do wytwarzania postaci leku z uwalnianiem substancji czynnej przy obniżonych wartościach pH
WO2008003958A3 (en) Fused pyrimido compounds
GEP20125410B (en) Solid preparation comprising alogliptin and pioglitazone
WO2006131721A3 (en) Topical ungual formulations
WO2008127364A3 (en) Antiviral compounds and use thereof
TW200833372A (en) Use of (meth)acrylate copolymers in delayed-release pharmaceutical forms for decreasing the influence of ethanol on the release of active compound
WO2007127263A3 (en) Therapeutic uses of urolithins
USD629114S1 (en) Set of bandages for a healing wound
WO2007025613A3 (en) Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain
WO2009040666A3 (en) Treatment of graft-versus-host disease
WO2006084164A8 (en) Gastric retention and controlled release delivery system
MX2010009222A (es) Soluciones farmaceuticas, proceso de preparacion y usos terapeuticos.
WO2007052299A3 (en) Controlled release formulation
WO2009013019A3 (en) Pharmaceutical preparations comprising electrochemically activated hypochlorite solutions
WO2007130822A3 (en) Mglur5 modulators iii
EG25586A (en) Coated fertiliser with a controlled release of active ingredients, and method for the production thereof
EP2180024A4 (en) HYDROPHILIC FILM-FORMING COMPOSITION, SPRAYING COMPOSITION AND HYDROPHILIC ELEMENT THEREWITH
GB2460590B (en) Adjuvant composition, agrochemical spray aqueous solution containing the same and control method using the same
EP2010570B8 (en) Therapy against cathepsin s
WO2008068299A3 (en) Hydrobromide salt of an anti-hiv compound
WO2008073863A3 (en) Preparation and utility of substituted allylamines
PL1845945T3 (pl) Wytwarzanie postaci dawkowania ze stałą dyspersją mikrokrystalicznego związku aktywnego
WO2008157563A3 (en) Deuterium-enriched clopidogrel
USD640006S1 (en) Fingernail coating application assistance device
EG25401A (en) Process for the preparation of urea.